OBJECTIVE: Genetic variants in the region of tumor necrosis factor-induced protein 3-interacting protein 1 (TNIP1) are associated with autoimmune disease and reduced TNIP1 gene expression. The aim of this study was to define the functional genetic mechanisms driving TNIP1 hypomorphic expression imparted by the systemic lupus erythematosus-associated TNIP1 H1 risk haplotype. METHODS: Dual luciferase expression and electrophoretic mobility shift assays were used to evaluate the allelic effects of 11 risk variants on enhancer function and nuclear protein binding in immune cell line models (Epstein-Barr virus [EBV]-transformed human B cells, Jurkat cells, and THP-1 cells), left in a resting state or stimulated with phorbol 12-myristate 13-acetate/ionomycin. HiChIP was used to define the regulatory 3-dimensional (3-D) chromatin network of the TNIP1 haplotype by detecting in situ long-range DNA contacts associated with H3K27ac-marked chromatin in EBV B cells. Then, quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was used to determine the expression of genes within the 3-D chromatin network. RESULTS: Bioinformatics analyses of 50 single-nucleotide polymorphisms on the TNIP1 H1 risk haplotype identified 11 non-protein-coding variants with a high likelihood of influencing TNIP1 gene expression. Eight variants in EBV B cells, 5 in THP-1 cells, and 2 in Jurkat cells exhibited various allelic effects on enhancer activation, resulting in a cumulative suppressive effect on TNIP1 expression (net effect of risk variants -7.14 fold, -6.80 fold, and -2.44 fold, respectively; n > 3). Specifically, in EBV B cells, only 2 variants (rs10057690 and rs13180950) exhibited allele-specific loss of both enhancer activity and nuclear protein binding (each P < 0.01 relative to nonrisk alleles). In contrast, the rs10036748 risk allele reduced binding affinities of the transcriptional repressors basic helix-loop-helix family member 40/differentially expressed in chondrocytes 1 (bHLHe40/DEC1) (P < 0.05 relative to nonrisk alleles) and CREB-1 (P not significant) in EBV B cells, resulting in a gain of enhancer activity (P < 0.05). HiChIP and qRT-PCR analyses revealed that overall transcriptional repression of the TNIP1 haplotype extended to the neighboring genes DCTN4 and GMA2, both of which also showed decreased expression in the presence of the TNIP1 risk haplotype (P < 0.001 and P < 0.01, respectively, relative to the nonrisk haplotype); notably, it was found that these genes share a 3-D chromatin network. CONCLUSION: Hypomorphic TNIP1 expression results from the combined concordant and opposing effects of multiple risk variants carried on the TNIP1 risk haplotype, with the strongest regulatory effect in B lymphoid lineage cells. Furthermore, the TNIP1 risk haplotype effect extends to neighboring genes within a shared chromatin network.
OBJECTIVE: Genetic variants in the region of tumor necrosis factor-induced protein 3-interacting protein 1 (TNIP1) are associated with autoimmune disease and reduced TNIP1 gene expression. The aim of this study was to define the functional genetic mechanisms driving TNIP1 hypomorphic expression imparted by the systemic lupus erythematosus-associated TNIP1 H1 risk haplotype. METHODS: Dual luciferase expression and electrophoretic mobility shift assays were used to evaluate the allelic effects of 11 risk variants on enhancer function and nuclear protein binding in immune cell line models (Epstein-Barr virus [EBV]-transformed human B cells, Jurkat cells, and THP-1 cells), left in a resting state or stimulated with phorbol 12-myristate 13-acetate/ionomycin. HiChIP was used to define the regulatory 3-dimensional (3-D) chromatin network of the TNIP1 haplotype by detecting in situ long-range DNA contacts associated with H3K27ac-marked chromatin in EBV B cells. Then, quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was used to determine the expression of genes within the 3-D chromatin network. RESULTS: Bioinformatics analyses of 50 single-nucleotide polymorphisms on the TNIP1 H1 risk haplotype identified 11 non-protein-coding variants with a high likelihood of influencing TNIP1 gene expression. Eight variants in EBV B cells, 5 in THP-1 cells, and 2 in Jurkat cells exhibited various allelic effects on enhancer activation, resulting in a cumulative suppressive effect on TNIP1expression (net effect of risk variants -7.14 fold, -6.80 fold, and -2.44 fold, respectively; n > 3). Specifically, in EBV B cells, only 2 variants (rs10057690 and rs13180950) exhibited allele-specific loss of both enhancer activity and nuclear protein binding (each P < 0.01 relative to nonrisk alleles). In contrast, the rs10036748 risk allele reduced binding affinities of the transcriptional repressors basic helix-loop-helix family member 40/differentially expressed in chondrocytes 1 (bHLHe40/DEC1) (P < 0.05 relative to nonrisk alleles) and CREB-1 (P not significant) in EBV B cells, resulting in a gain of enhancer activity (P < 0.05). HiChIP and qRT-PCR analyses revealed that overall transcriptional repression of the TNIP1 haplotype extended to the neighboring genes DCTN4 and GMA2, both of which also showed decreased expression in the presence of the TNIP1 risk haplotype (P < 0.001 and P < 0.01, respectively, relative to the nonrisk haplotype); notably, it was found that these genes share a 3-D chromatin network. CONCLUSION: Hypomorphic TNIP1expression results from the combined concordant and opposing effects of multiple risk variants carried on the TNIP1 risk haplotype, with the strongest regulatory effect in B lymphoid lineage cells. Furthermore, the TNIP1 risk haplotype effect extends to neighboring genes within a shared chromatin network.
Authors: K X Yan; Y J Zhang; L Han; Q Huang; Z H Zhang; X Fang; Z Z Zheng; N Yawalkar; Y L Chang; Q Zhang; L Jin; D F Qian; X Y Li; M S Wu; Q H Xu; X J Zhang; J H Xu Journal: Br J Dermatol Date: 2019-04-24 Impact factor: 9.302
Authors: Xingnan Li; Elizabeth J Ampleford; Timothy D Howard; Wendy C Moore; Dara G Torgerson; Huashi Li; William W Busse; Mario Castro; Serpil C Erzurum; Elliot Israel; Dan L Nicolae; Carole Ober; Sally E Wenzel; Gregory A Hawkins; Eugene R Bleecker; Deborah A Meyers Journal: J Allergy Clin Immunol Date: 2012-06-12 Impact factor: 10.793
Authors: Jeremy P Huynh; Chih-Chung Lin; Jacqueline M Kimmey; Nicholas N Jarjour; Elizabeth A Schwarzkopf; Tara R Bradstreet; Irina Shchukina; Oleg Shpynov; Casey T Weaver; Reshma Taneja; Maxim N Artyomov; Brian T Edelson; Christina L Stallings Journal: J Exp Med Date: 2018-05-17 Impact factor: 14.307
Authors: Alan P Boyle; Eurie L Hong; Manoj Hariharan; Yong Cheng; Marc A Schaub; Maya Kasowski; Konrad J Karczewski; Julie Park; Benjamin C Hitz; Shuai Weng; J Michael Cherry; Michael Snyder Journal: Genome Res Date: 2012-09 Impact factor: 9.043
Authors: Dawn J Caster; Erik A Korte; Sambit K Nanda; Kenneth R McLeish; Rebecca K Oliver; Rachel T G'sell; Ryan M Sheehan; Darrell W Freeman; Susan C Coventry; Jennifer A Kelly; Joel M Guthridge; Judith A James; Kathy L Sivils; Marta E Alarcon-Riquelme; R Hal Scofield; Indra Adrianto; Patrick M Gaffney; Anne M Stevens; Barry I Freedman; Carl D Langefeld; Betty P Tsao; Bernardo A Pons-Estel; Chaim O Jacob; Diane L Kamen; Gary S Gilkeson; Elizabeth E Brown; Graciela S Alarcon; Jeffrey C Edberg; Robert P Kimberly; Javier Martin; Joan T Merrill; John B Harley; Kenneth M Kaufman; John D Reveille; Juan-Manuel Anaya; Lindsey A Criswell; Luis M Vila; Michelle Petri; Rosalind Ramsey-Goldman; Sang-Cheol Bae; Susan A Boackle; Timothy J Vyse; Timothy B Niewold; Philip Cohen; David W Powell Journal: J Am Soc Nephrol Date: 2013-08-22 Impact factor: 10.121
Authors: Richard C Pelikan; Jennifer A Kelly; Yao Fu; Caleb A Lareau; Kandice L Tessneer; Graham B Wiley; Mandi M Wiley; Stuart B Glenn; John B Harley; Joel M Guthridge; Judith A James; Martin J Aryee; Courtney Montgomery; Patrick M Gaffney Journal: Nat Commun Date: 2018-07-25 Impact factor: 17.694
Authors: Ammar J Alsheikh; Sabrina Wollenhaupt; Emily A King; Jonas Reeb; Sujana Ghosh; Lindsay R Stolzenburg; Saleh Tamim; Jozef Lazar; J Wade Davis; Howard J Jacob Journal: BMC Med Genomics Date: 2022-04-01 Impact factor: 3.063
Authors: Satish Pasula; Jaanam Gopalakrishnan; Yao Fu; Kandice L Tessneer; Mandi M Wiley; Richard C Pelikan; Jennifer A Kelly; Patrick M Gaffney Journal: Front Genet Date: 2022-09-19 Impact factor: 4.772